PainReform (NASDAQ:PRFX) Stock Price Down 1.3% – Here’s Why

PainReform Ltd. (NASDAQ:PRFX)’s stock price dropped 1.3% on Monday . The company traded as low as $0.87 and last traded at $0.8838. Approximately 96,867 shares were traded during trading, a decline of 86% from the average daily volume of 695,639 shares. The stock had previously closed at $0.8955.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PRFX. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a report on Wednesday, October 8th. Wall Street Zen upgraded PainReform from a “strong sell” rating to a “hold” rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, PainReform has a consensus rating of “Sell”.

PainReform Stock Up 5.6%

The company’s 50-day moving average is $1.26 and its two-hundred day moving average is $1.51. The company has a market capitalization of $1.78 million, a P/E ratio of -0.01 and a beta of 0.61.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.